.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,952,062

« Back to Dashboard

Claims for Patent: 8,952,062

Title:Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Abstract: Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.
Inventor(s): Cook; Harry (Eden Prairie, MN), Hamilton; Martha (St. Paul, MN), Danielson; Douglas (Otsego, MI), Goderstad; Colette (St. Paul, MN), Reardan; Dayton T. (Shorewood, MN)
Assignee: Jazz Pharmaceuticals, Inc. (Palo Alto, CA)
Application Number:13/787,437
Patent Claims: 1. A method of treating a condition responsive to gamma-hydroxybutyrate comprising orally administering two doses to a patient afflicted with the condition: (i) an aqueous composition comprising a first dose of about 3 to about 10 grams of salt of gamma-hydroxybutyrate; and (ii) an aqueous composition comprising a second dose of about 3 to about 10 grams of a salt of gamma-hydroxybutyrate within 2.0 to 5 hours after the first dose; wherein two doses are administered to the patient for a total amount of between 6 to 20 grams per day wherein the aqueous composition of the first dose and the aqueous composition of the second dose each were prepared by diluting a solution of gamma-hydroxybutyrate of 350 to 750 mg/ml.

2. The method of claim 1, wherein the condition is selected from the group consisting of apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.

3. The method of claim 1, wherein the aqueous composition of the first dose and the aqueous composition of the second dose each were prepared from a solution of gamma-hydroxybutyrate of 450 to 750 mg/ml.

4. The method of claim 3, wherein the solution of 450 to 750 mg/ml has a pH of about 7.0 to about 9.0, is chemically stable and resistant to microbial growth, and does not require preservatives.

5. The method of claim 1, wherein the salt is selected from the group consisting of sodium, ammonium, calcium and magnesium forms of gamma-hydroxybutyrate.

6. The method of claim 1, wherein the aqueous composition contains one or more of salts selected from the group consisting of lithium, potassium, sodium, calcium, ammonium, and magnesium.

7. The method of claim 1, wherein the second dose is administered within about 2.0, about 2.1, about 2.2, about 2.3, about 2.4, about 2.5, about 2.6, about 2.7, about 2.8, about 2.9, about 3.0, about 3.1, about 3.2, about 3.3, about 3.4, about 3.5, about 3.6, about 3.7, about 3.8, about 3.9, about 4.0, about 4.1, about 4.2, about 4.3, about 4.4, about 4.5, about 4.6, about 4.7, about 4.8, about 4.9, or about 5.0 hours after the first dose.

8. A method of treating a condition responsive to gamma-hydroxybutyrate comprising orally administering to a patient afflicted with the condition: (i) an aqueous composition comprising a first dose of about 1.0 to about 4.5 grams of a salt of gamma-hydroxybutyrate; and (ii) an aqueous composition comprising a second dose of about 1.0 to about 4.5 grams of a salt of gamma-hydroxybutyrate within 2.0 to 5 hours after the first dose; wherein the aqueous composition of the first dose and the aqueous composition of the second dose each were prepared from a solution of gamma-hydroxybutyrate of 350 to 750 mg/ml.

9. The method of claim 8, wherein the condition is selected from the group consisting of apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.

10. The method of claim 8, wherein the solution has a pH of about 7.0 to about 9.0, is chemically stable and resistant to microbial growth, and does not require preservatives.

11. The method of claim 8, wherein the salt is selected from the group consisting of sodium, ammonium, calcium and magnesium forms of gamma-hydroxybutyrate.

12. The method of claim 8, wherein the aqueous composition contains one or more salts selected from the group consisting of lithium, potassium, sodium, calcium, ammonium, and magnesium.

13. The method of claim 8, wherein the aqueous composition of the first dose and the aqueous composition of the second dose each comprises about 2.25 to about 4.5 grams of the salt of gamma-hydroxybutyrate.

14. The method of claim 8, wherein the aqueous composition of the first dose and the aqueous composition of the second dose each comprises about 1.0 to about 3.0 grams of the salt of gamma-hydroxybutyrate.

15. A method of treating a condition responsive to sodium gamma-hydroxybutyrate, comprising (i) diluting a solution comprising about 500 mg/mL of sodium gamma-hydroxybutyrate with an aqueous medium to provide a first dose of about 3 to about 4.5 grams of sodium gamma-hydroxybutyrate; (ii) diluting a solution comprising about 500 mg/mL of sodium gamma-hydroxybutyrate with an aqueous medium to provide a second dose of about 3 to about 4.5 grams of sodium gamma-hydroxybutyrate; (iii) orally administering to a patient afflicted with the condition the first dose; (iv) orally administering to a patient afflicted with the condition the second dose within 2.5 to 4 hours after the first dose; wherein the condition is cataplexy or daytime sleepiness in a patient with narcolepsy.

16. The method of claim 15 in which each dose of from about 3 to about 4.5 grams of sodium gamma-hydroxybutyrate is prepared by diluting a solution comprising about 500 mg/mL of sodium gamma-hydroxybutyrate with about 60 mL of water.

17. The method of claim 15, wherein the first dose is orally administered to the patient immediately prior to bedtime.

18. A method of treating a condition responsive to sodium gamma-hydroxybutyrate, comprising (i) diluting a solution comprising about 500 mg/mL of sodium gamma-hydroxybutyrate with an aqueous medium to provide a first dose of about 3 to about 5 grams of sodium gamma-hydroxybutyrate; (ii) diluting a solution comprising about 500 mg/mL of sodium gamma-hydroxybutyrate with an aqueous medium to provide a second dose of about 3 to about 5 grams of sodium gamma-hydroxybutyrate; (iii) orally administering to a patient afflicted with the condition the first dose; (iv) orally administering to a patient afflicted with the condition the second dose within 2.5 to 4 hours after the first dose; wherein the condition is cataplexy or daytime sleepiness in a patient with narcolepsy.

19. The method of claim 18, wherein each diluted dose contains about 50 mg/mL to about 167 mg/mL sodium gamma-hydroxybutyrate.

20. The method of claim 18, wherein each dose is about 3 to about 4.5 grams of sodium gamma-hydroxybutyrate.

21. The method of claim 20, wherein each diluted dose contains about 50 mg/mL to about 75 mg/mL sodium gamma-hydroxybutyrate.

22. The method of claim 18, wherein the first dose is orally administered to the patient immediately prior to bedtime.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc